Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13918966 | 0.85 | ALDH1A1 (0.47) | MEN1KMT2ASIGMAR1TMEM97HIF1A | |
| SCHEMBL16559754 | 0.85 | SIGMAR1 (0.40) | MEN1KMT2ASIGMAR1TMEM97HIF1A | |
| SCHEMBL19852567 | 0.84 | BCHE (0.42) | MEN1KMT2ASIGMAR1TMEM97HIF1A | |
| SCHEMBL13336035 | 0.81 | KDM4E (0.43) | SIGMAR1TMEM97HIF1AKDM4EALDH1A1 | |
| SCHEMBL4678470 | 0.79 | CYP2C19 (0.52) | ALDH1A1HPGDACHELMNAHDAC4 | |
| SCHEMBL17300702 | 0.78 | ACHE (0.42) | MEN1KMT2ASIGMAR1TMEM97HIF1A | |
| SCHEMBL13175212 | 0.78 | CYP2D6 (0.56) | SIGMAR1BRD4PDCD1CD274HSD17B10 | |
| SCHEMBL10223554 | 0.78 | SIGMAR1 (0.58) | SIGMAR1 | |
| SCHEMBL16217382 | 0.77 | AOC3 (0.47) | MEN1KMT2ASIGMAR1TMEM97HIF1A | |
| SCHEMBL7976714 | 0.77 | HSD11B1 (0.45) | SIGMAR1BRD4PDCD1CD274HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352343-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210380588-A1 | Novel Compounds and Uses Thereof | OXFORD FINANCE LLC | 2021-12-09 | — | — | US | disclosed |
| US-10954244-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200299272-A1 | Urea Derivatives and Uses Thereof | KALA BIO, Inc. | 2020-09-24 | — | — | US | disclosed |
| US-10723719-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200157106-A1 | Novel Compounds and Uses Thereof | KALA BIO, Inc. | 2020-05-21 | — | — | US | disclosed |
| US-10544151-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190284172-A1 | Urea Derivatives and Uses Thereof | KALA BIO, Inc. | 2019-09-19 | — | — | US | disclosed |
| US-10351570-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10329280-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20170129876-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2017-05-11 | — | — | US | disclosed |
| US-20170129876-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2017-05-11 | — | — | US | disclosed |
| US-9580421-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580421-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160137646-A1 | Novel Compounds and Uses Thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160137646-A1 | Novel Compounds and Uses Thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160060264-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2016-03-03 | — | — | US | disclosed |
| US-20160060264-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2016-03-03 | — | — | US | disclosed |
| US-9212145-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150072986-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072986-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | MEN1 2165/4885KMT2A 4792/4885SIGMAR1 3645/4885 |
| US-20160137646-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | MEN1 1981/4885KMT2A 4801/4885SIGMAR1 4247/4885 |
| US-11352343-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | MEN1 2165/4885KMT2A 4792/4885SIGMAR1 3645/4885 |
| US-20210380588-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | MEN1 1981/4885KMT2A 4801/4885SIGMAR1 4247/4885 |
| US-20200157106-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | MEN1 1981/4885KMT2A 4801/4885SIGMAR1 4247/4885 |
| US-10544151-B2 | Compounds and uses thereof | RB1, VEGFA, KDR | MEN1 2105/4885KMT2A 4786/4885SIGMAR1 4297/4885 |
| US-10954244-B2 | Compounds and uses thereof | RB1, VEGFA, FLT4 | MEN1 2005/4885KMT2A 4789/4885SIGMAR1 4299/4885 |
| US-10723719-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | MEN1 2165/4885KMT2A 4792/4885SIGMAR1 3645/4885 |
| US-20200299272-A1 | Urea Derivatives and Uses Thereof | UACA, RB1, FLT1 | MEN1 2165/4885KMT2A 4792/4885SIGMAR1 3645/4885 |
| US-10329280-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | MEN1 2165/4885KMT2A 4792/4885SIGMAR1 3645/4885 |
| US-20190284172-A1 | Urea Derivatives and Uses Thereof | UACA, RB1, FLT1 | MEN1 2165/4885KMT2A 4792/4885SIGMAR1 3645/4885 |
| US-10351570-B2 | Compounds and uses thereof | RB1, VEGFA, FLT4 | MEN1 2005/4885KMT2A 4789/4885SIGMAR1 4299/4885 |
| US-20170129876-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | MEN1 2165/4885KMT2A 4792/4885SIGMAR1 3645/4885 |
| US-20160060264-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | MEN1 2165/4885KMT2A 4792/4885SIGMAR1 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.